API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Multi-center, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of daily oral BGE-175 for up to 14 days.
Lead Product(s): Asapiprant
Therapeutic Area: Infections and Infectious Diseases Product Name: BGE-175
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
With this agreement, Shionogi grants BioAge exclusive U.S. and European rights to develop and commercialize BGE-175 for COVID-19 treatment. In addition, Shionogi grants BioAge exclusive rights to negotiate a license for additional indications.
Lead Product(s): Asapiprant
Therapeutic Area: Infections and Infectious Diseases Product Name: BGE-175
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioAge Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2021
Details:
The compound, BGE-175, is a potent orally administered inhibitor of the prostaglandin D2 (PGD2) DP1 signaling pathway associated with increased risk of mortality, and susceptibility to infections.
Lead Product(s): Asapiprant
Therapeutic Area: Infections and Infectious Diseases Product Name: BGE-175
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020